Thinking outside the Box
Innovation at the cutting edge, cube houses in Rotterdam designed by Piet Blom
Continuing our CAR-T cell therapy mini-series, we take a look at how some creative preclinical studies helped uncover a new mechanism of resistance to CAR-T therapy.
This then led to a novel enhancement or tweak in the engineering of the CAR-T cells in order to make them resistant to being killed themselves. These twin findings could lead to the enhancement of performance in the clinic for patients needing such treatment.
If we want to help more lymphoma patients get to the 6 month mark and beyond then we need greater understanding of the underlying issues combined with practical thinking skills.
In our latest expert interview, we discuss an innovative new cell therapy approach with an unusual strategy currently in preclinical development, which is heading towards the clinic …
To continue reading our latest highlights on oncology new product development, including expert commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
